(ZEROHEDGE) – Shares of Danish pharmaceutical giant Novo Nordisk A/S soared to a new record high on Thursday after the company reported progress in its pill-based next-generation obesity treatment during an investor event.
Investors cheered when Novo released the results of a Phase I trial of the amycretin pill version, which showed participants lost about 13.1% after 12 weeks. This compares to a 6% weight loss drop after 12 weeks in the trial for its injectable Wegovy drug.
Amycretin uses the same GLP-1 hormone as other weight-loss drugs, such as Wegovy and Lilly's Zepbound. The key is that it also stimulates the hormone amylin, which regulates hunger.